Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.

Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, Ehrchen J, Sondermann W, Pul R, Kleinschnitz C, Wiendl H, Meuth SG, Klotz L.

Neurology. 2018 Nov 7. pii: 10.1212/WNL.0000000000006648. doi: 10.1212/WNL.0000000000006648. [Epub ahead of print]

PMID:
30404783
2.

Sarcoidosis following alemtuzumab treatment: Autoimmunity mediated by T cells and interferon-γ.

Pfeuffer S.

Mult Scler. 2018 Nov;24(13):1783-1784. doi: 10.1177/1352458518804124. Epub 2018 Oct 11. No abstract available.

PMID:
30307361
3.

Association of smoking but not HLA-DRB1*15:01, APOE or body mass index with brain atrophy in early multiple sclerosis.

Graetz C, Gröger A, Luessi F, Salmen A, Zöller D, Schultz J, Siller N, Fleischer V, Bellenberg B, Berthele A, Biberacher V, Havla J, Hecker M, Hohlfeld R, Infante-Duarte C, Kirschke JS, Kümpfel T, Linker R, Paul F, Pfeuffer S, Sämann P, Toenges G, Weber F, Zettl UK, Jahn-Eimermacher A, Antony G, Groppa S, Wiendl H, Hemmer B, Mühlau M, Lukas C, Gold R, Lill CM, Zipp F.

Mult Scler. 2018 Mar 1:1352458518763541. doi: 10.1177/1352458518763541. [Epub ahead of print]

PMID:
29532745
4.

Alemtuzumab Improves Cognitive Processing Speed in Active Multiple Sclerosis-A Longitudinal Observational Study.

Riepl E, Pfeuffer S, Ruck T, Lohmann H, Wiendl H, Meuth SG, Johnen A.

Front Neurol. 2018 Jan 16;8:730. doi: 10.3389/fneur.2017.00730. eCollection 2017.

5.

An Enigmatic Case of Acute Mercury Poisoning: Clinical, Immunological Findings and Platelet Function.

Kleffner I, Eichler S, Ruck T, Schüngel L, Pfeuffer S, Polzer P, Dittrich R, Dziewas R, Gross CC, Göbel K, Wiendl H, Kehrel BE, Meuth SG.

Front Neurol. 2017 Sep 28;8:517. doi: 10.3389/fneur.2017.00517. eCollection 2017.

6.

Acute cholecystitis during treatment with alemtuzumab in 3 patients with RRMS.

Pfeuffer S, Beuker C, Ruck T, Lenze F, Wiendl H, Melzer N, Meuth SG.

Neurology. 2016 Nov 29;87(22):2380-2381. Epub 2016 Oct 28. No abstract available.

PMID:
27794114
7.

Epithelial IL-23R Signaling Licenses Protective IL-22 Responses in Intestinal Inflammation.

Aden K, Rehman A, Falk-Paulsen M, Secher T, Kuiper J, Tran F, Pfeuffer S, Sheibani-Tezerji R, Breuer A, Luzius A, Jentzsch M, Häsler R, Billmann-Born S, Will O, Lipinski S, Bharti R, Adolph T, Iovanna JL, Kempster SL, Blumberg RS, Schreiber S, Becher B, Chamaillard M, Kaser A, Rosenstiel P.

Cell Rep. 2016 Aug 23;16(8):2208-2218. doi: 10.1016/j.celrep.2016.07.054. Epub 2016 Aug 11.

8.

Failed, interrupted and inconclusive trials on relapsing multiple sclerosis treatment: update 2010-2015.

Pfeuffer S, Ruck T, Kleinschnitz C, Wiendl H, Meuth SG.

Expert Rev Neurother. 2016 Jun;16(6):689-700. doi: 10.1080/14737175.2016.1176531. Epub 2016 Apr 25. Review.

PMID:
27058174
9.

Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.

Obermann M, Ruck T, Pfeuffer S, Baum J, Wiendl H, Meuth SG.

Mult Scler. 2016 Aug;22(9):1235-41. doi: 10.1177/1352458516638558. Epub 2016 Mar 15. Review.

PMID:
26980848
10.

ALAIN01--Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.

Ruck T, Afzali AM, Lukat KF, Eveslage M, Gross CC, Pfeuffer S, Bittner S, Klotz L, Melzer N, Wiendl H, Meuth SG.

BMC Neurol. 2016 Mar 10;16:34. doi: 10.1186/s12883-016-0556-9.

11.

QA professionals can utilize hospital information systems.

Pfeuffer S.

Tex Hosp. 1985 Oct;41(5):36-7. No abstract available.

PMID:
10275727

Supplemental Content

Loading ...
Support Center